Management of relapsed and refractory multiple myeloma: Novel agents, antibodies, immunotherapies and beyond

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989 · see citing works

The blockade of immune checkpoints in cancer immunotherapy

Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · see citing works

Oncology meets immunology: the cancer-immunity cycle.

Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929 · see citing works

Multiple Myeloma

Palumbo, A. P., & Anderson, K. C. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011442 · Cited by 2,338 · see citing works

Multiple myeloma

Raje, N. S., & Anderson, K. C. (2000) · Current Treatment Options in Oncology · doi:10.1007/s11864-000-0017-x · Cited by 2,164 · see citing works

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

Palumbo, A., Chanan-Khan, A., Weisel, K., Nooka, A. K., Masszi, T., Beksac, M., Spicka, I., Hungria, V., Munder, M., Mateos, M. V., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606038 · Cited by 1,522 · see citing works

CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION

Bladé, J., Samson, D., Reece, D. E., Apperley, J. F., Björkstrand, B., Gahrton, G., Gertz, M. A., Giralt, S. A., Jagannath, S., & Vesole, D. H. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,516 · see citing works

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Dimopoulos, M. A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N. J., Usmani, S. Z., Rabin, N., Orlowski, R. Z., Komarnicki, M., Suzuki, K., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607751 · Cited by 1,445 · see citing works

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Mihaylov, G. G., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411321 · Cited by 1,332 · see citing works

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

Lonial, S., Dimopoulos, M., Palumbo, A., White, D., Grosicki, S., Spicka, I., Walter-Croneck, A., Moreau, P., Mateos, M.-V., Magen, H., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505654 · Cited by 1,322 · see citing works

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

Lokhorst, H. M., Plesner, T., Laubach, J. P., Nahi, H., Gimsing, P., Hansson, M., Minnema, M. C., Lassen, U., Krejcik, J., Palumbo, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506348 · Cited by 1,117 · see citing works

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

Moreau, P., Masszi, T., Grzasko, N., Bahlis, N. J., Hansson, M., Pour, L., Sandhu, I., Ganly, P., Baker, B. W., Jackson, S. R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516282 · Cited by 1,060 · see citing works

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

Rajkumar, S. V., Harousseau, J.-L., Durie, B., Anderson, K. C., Dimopoulos, M., Kyle, R., Blade, J., Richardson, P., Orlowski, R., Siegel, D., et al. (2011) · Blood · doi:10.1182/blood-2010-10-299487 · Cited by 1,036 · see citing works

Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma

Krejcik, J., Casneuf, T., Nijhof, I. S., Verbist, B. M. P., Bald, J., Plesner, T., Syed, K. W., Liu, K., van de Donk, N. W. C. J., Weiss, B. M., et al. (2016) · Blood · doi:10.1182/blood-2015-12-687749 · Cited by 961 · see citing works

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

Dimopoulos, M. A., Moreau, P., Palumbo, A. P., Joshua, D., Pour, L., Hájek, R., Facon, T. T. F., Ludwig, H., Oriol, A., Goldschmidt, H., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00464-7 · Cited by 858 · see citing works

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

Lonial, S., Weiss, B. M., Usmani, S. Z., Singhal, S., Chari, A., Bahlis, N. J., Belch, A., Krishnan, A., Vescio, R. A., Mateos, M. V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01120-4 · Cited by 854 · see citing works

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

Miguel, J. F. S., Weisel, K. C., Moreau, P., Lacy, M. Q., Song, K., Delforge, M., Karlin, L., Goldschmidt, H., Banos, A., Oriol, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70380-2 · Cited by 800 · see citing works

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

Miguel, J. F. S., Hungria, V., Yoon, S., Beksaç, M., Dimopoulos, M. A., Elghandour, A., Wiktor-Jędrzejczak, W., Günther, A., Nakorn, T. N., Siritanaratkul, N., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70440-1 · Cited by 793 · see citing works

T cells expressing an anti–B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma

Ali, S. A., Shi, V., Marić, I., Wang, M. L., Stroncek, D. F., Rose, J. J., Brudno, J. N., Stetler‐Stevenson, M., Feldman, S. A., Hansen, B. G., et al. (2016) · Blood · doi:10.1182/blood-2016-04-711903 · Cited by 760 · see citing works

Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma

Garfall, A. L., Maus, M. V., Hwang, W.-T., Lacey, S. F., Mahnke, Y. D., Melenhorst, J. J., Zheng, Z., Vogl, D. T., Cohen, A. D., Weiss, B. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504542 · Cited by 624 · see citing works

Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma

Hideshima, T., Bradner, J. E., Wong, J. Y. Y., Chauhan, D., Richardson, P. G. G., Schreiber, S. L., & Anderson, K. C. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503221102 · Cited by 598 · see citing works

Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu

Tai, Y., Dillon, M., Song, W., Leiba, M., Li, X.-F., Burger, P., Lee, A. I., Podar, K., Hideshima, T., Rice, A. G., et al. (2007) · Blood · doi:10.1182/blood-2007-08-107292 · Cited by 472 · see citing works

Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma

Chari, A., Suvannasankha, A., Fay, J. W., Arnulf, B., Kaufman, J. L., Ifthikharuddin, J. J., Weiss, B. M., Krishnan, A. Y., Lentzsch, S., Comenzo, R. L., et al. (2017) · Blood · doi:10.1182/blood-2017-05-785246 · Cited by 444 · see citing works

Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma

Usmani, S. Z., Weiss, B. M., Plesner, T., Bahlis, N. J., Belch, A., Lonial, S., Lokhorst, H. M., Voorhees, P. M., Richardson, P. G., Chari, A., et al. (2016) · Blood · doi:10.1182/blood-2016-03-705210 · Cited by 407 · see citing works

Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides

Egan, J. B., Shi, C.-X., Tembe, W., Christoforides, A., Kurdoglu, A. A., Sinari, S. A., Middha, S., Asmann, Y. W., Schmidt, J. E., Braggio, E., et al. (2012) · Blood · doi:10.1182/blood-2012-01-405977 · Cited by 404 · see citing works

International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation.

Palumbo, A., Rajkumar, S., Miguel, J. S. S., Larocca, A., Niesvizky, R., Morgan, G., Landgren, O., Hájek, R., Einsele, H., Anderson, K., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.48.7934 · Cited by 385 · see citing works

Aggresome induction by proteasome inhibitor bortezomib and α-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells

Catley, L. P., Weisberg, E., Kiziltepe, T., Tai, Y., Hideshima, T., Neri, P., Tassone, P., Atadja, P. W., Chauhan, D., Munshi, N. C., et al. (2006) · Blood · doi:10.1182/blood-2006-04-016055 · Cited by 335 · see citing works

CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications

Tai, Y.-T., Landesman, Y., Acharya, C., Calle, Y., Zhong, M., Cea, M., Tannenbaum, D., Cagnetta, A., Reagan, M. R., Munshi, A., et al. (2013) · Leukemia · doi:10.1038/leu.2013.115 · Cited by 309 · see citing works

Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC

Collins, S. M., Bakan, C. E., Swartzel, G. D., Hofmeister, C. C., Efebera, Y. A., Kwon, H., Starling, G. C., Ciarlariello, D., Bhaskar, S., Briercheck, E. L., et al. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1493-8 · Cited by 296 · see citing works

Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology

Kumar, S. K., Callander, N. S., Alsina, M., Atanackovic, D., Biermann, J. S., Chandler, J. C., Costello, C., Faiman, M., Fung, H. C., Gasparetto, C., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0023 · Cited by 279 · see citing works

Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma

Vogl, D. T., Raje, N. S., Jagannath, S., Richardson, P. G. G., Hari, P., Orlowski, R. Z., Supko, J. G., Tamang, D., Yang, M., Jones, S. S., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2526 · Cited by 260 · see citing works

Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma

Shah, J. J., Stadtmauer, E. A., Abonour, R., Cohen, A. D., Bensinger, W., Gasparetto, C., Kaufman, J. L., Lentzsch, S., Vogl, D. T., Gomes, C. L., et al. (2015) · Blood · doi:10.1182/blood-2015-05-643320 · Cited by 225 · see citing works

The role of complete response in multiple myeloma

Harousseau, J., Attal, M., & Avet‐Loiseau, H. (2009) · Blood · doi:10.1182/blood-2009-03-201053 · Cited by 221 · see citing works

Autophagy inhibition enhances vorinostat‐induced apoptosis via ubiquitinated protein accumulation

Carew, J. S., Medina, E. C., Esquivel, J., Mahalingam, D., Swords, R. T., Kelly, K. R., Zhang, H., Huang, P., Mita, A. C., Mita, M. M., et al. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00832.x · Cited by 219 · see citing works

Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma

van de Donk, N. W. C. J., Moreau, P., Plesner, T., Palumbo, A. P., Gay, F., Laubach, J. P., Malavasi, F., Avet‐Loiseau, H., Mateos, M., Sonneveld, P., et al. (2015) · Blood · doi:10.1182/blood-2015-10-646810 · Cited by 204 · see citing works

Treatment of relapsed and refractory multiple myeloma

Sonneveld, P., & Broijl, A. (2016) · Haematologica · doi:10.3324/haematol.2015.129189 · Cited by 176 · see citing works

American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma

Giralt, S. A., Garderet, L., Durie, B. G. M., Cook, G., Gahrton, G., Bruno, B., Hari, P., Lokhorst, H. M., McCarthy, P., Krishnan, A. Y., et al. (2015) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2015.09.016 · Cited by 167 · see citing works

Achievement of at Least Very Good Partial Response Is a Simple and Robust Prognostic Factor in Patients With Multiple Myeloma Treated With High-Dose Therapy: Long-Term Analysis of the IFM 99-02 and 99-04 Trials

Harousseau, J., Avet‐Loiseau, H., Attal, M., Guérin‐Charbonnel, C., Garban, F., Hulin, C., Michallet, M., Facon, T. T. F., Garderet, L., Marit, G., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.1060 · Cited by 164 · see citing works

Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma

Baz, R., Martin, T. G., Lin, H., Zhao, X., Shain, K. H., Cho, H. J., Wolf, J. L., Mahindra, A. K., Chari, A., Sullivan, D. M., et al. (2016) · Blood · doi:10.1182/blood-2015-11-682518 · Cited by 159 · see citing works

High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial

Cook, G., Williams, C. D., Brown, J. M., Cairns, D. A., Cavenagh, J. D., Snowden, J. A., Ashcroft, A. J., Fletcher, M., Parrish, C., Yong, K., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70245-1 · Cited by 151 · see citing works

The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial

Cook, G., Ashcroft, A. J., Cairns, D. A., Williams, C. D., Brown, J. M., Cavenagh, J. D., Snowden, J. A., Parrish, C., Yong, K., Cavet, J., et al. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(16)30049-7 · Cited by 147 · see citing works

Oligoclonal Protein Bands and Ig Isotype Switching in Multiple Myeloma Treated With High-Dose Therapy and Hematopoietic Cell Transplantation

Zent, C. S., Wilson, C. S., Tricot, G. J. K., Jagannath, S., Siegel, D. S. D., Desikan, K. R., Munshi, N. C., Bracy, D., Barlogie, B., & Butch, A. W. (1998) · Blood · doi:10.1182/blood.v91.9.3518 · Cited by 126 · see citing works

Targeting the PD-1/PD-L1 axis in multiple myeloma: a dream or a reality?

Rosenblatt, J. M., & Avigan, D. (2016) · Blood · doi:10.1182/blood-2016-08-731885 · Cited by 116 · see citing works

Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re‐treatment with daratumumab among refractory patients

Nooka, A. K., Joseph, N. S., Kaufman, J. L., Heffner, L. T., Gupta, V. A., Gleason, C. L., Boise, L., & Lonial, S. (2019) · Cancer · doi:10.1002/cncr.32178 · Cited by 91 · see citing works

Pembrolizumab in Combination with Lenalidomide and Low-Dose Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM): Keynote-023

Miguel, J. F. S., Mateos, M., Shah, J. J., Ocio, E. M., Rodríguez‐Otero, P., Reece, D. E., Munshi, N. C., Avigan, D., Ge, Y., Balakumaran, A., et al. (2015) · Blood · doi:10.1182/blood.v126.23.505.505 · Cited by 88 · see citing works

Molecular Pathways: Anticancer Activity by Inhibition of Nucleocytoplasmic Shuttling

Conforti, F., Wang, Y., Rodríguez, J. A., Alberobello, A. T., Zhang, Y.-W., & Giaccone, G. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0408 · Cited by 87 · see citing works

Durable remissions with BCMA-specific chimeric antigen receptor (CAR)-modified T cells in patients with refractory/relapsed multiple myeloma.

Fan, F. (., Zhao, W., Liu, J., He, A., Chen, Y., Cao, X.-M., Yang, N., Wang, B., Zhang, P., Zhang, Y., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.lba3001 · Cited by 83 · see citing works

Next-generation multiple myeloma treatment: a pharmacoeconomic perspective

Rajkumar, S. V., & Harousseau, J. L. (2016) · Blood · doi:10.1182/blood-2016-09-692947 · Cited by 80 · see citing works

Allogeneic Stem Cell Transplantation in Multiple Myeloma Relapsed after Autograft: A Multicenter Retrospective Study Based on Donor Availability

Patriarca, F. F., Einsele, H., Spina, F., Bruno, B., Isola, M., Nozzoli, C., Nozza, A., Sperotto, A. A., Morabito, F., Stuhler, G., et al. (2011) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2011.07.026 · Cited by 80 · see citing works

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma

Paludo, J., Mikhael, J. R., LaPlant, B. R., Halvorson, A. E., Kumar, S. K., Gertz, M. A., Hayman, S. R., Buadi, F. K., Dispenzieri, A. A., Lust, J. A., et al. (2017) · Blood · doi:10.1182/blood-2017-05-782961 · Cited by 78 · see citing works

Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study

Moreau, P., Joshua, D. E., Chng, W.-J., Palumbo, A. P., Goldschmidt, H., Hájek, R., Facon, T. T. F., Ludwig, H., Pour, L., Niesvizky, R., et al. (2016) · Leukemia · doi:10.1038/leu.2016.186 · Cited by 77 · see citing works

Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma

de Lavallade, H., Cheikh, J. E., Faucher, C., Fürst, S., Am, S., Coso, D., Bouabdallah, R., Chabannon, C., Gastaut, J. A., Blaise, D., et al. (2008) · Bone Marrow Transplantation · doi:10.1038/bmt.2008.22 · Cited by 68 · see citing works

Durable remissions with BCMA-specific chimeric antigen receptor (CAR)-modified T cells in patients with refractory/relapsed multiple myeloma.

Fan, F. (., Zhao, W., Liu, J., He, A., Chen, Y., Cao, X.-M., Yang, N., Wang, B., Zhang, P., Zhang, Y., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.18_suppl.lba3001 · Cited by 66 · see citing works

Second transplants for multiple myeloma relapsing after a previous autotransplant—reduced-intensity allogeneic vs autologous transplantation

Freytes, C. O., Vesole, D. H., Le-Rademacher, J., Zhong, X., Gale, R. P., Kyle, R. A., Reece, D. E., Gibson, J., Schouten, H. C., McCarthy, P., et al. (2013) · Bone Marrow Transplantation · doi:10.1038/bmt.2013.187 · Cited by 56 · see citing works

A Phase II Study of Anti PD-1 Antibody Pembrolizumab, Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Badros, A. Z., Kocoglu, M. H., Ma, N., Rapoport, A. P., Lederer, E., Philip, S., Lesho, P., Dell, C. A., Hardy, N. M., Yared, J. A., et al. (2015) · Blood · doi:10.1182/blood.v126.23.506.506 · Cited by 55 · see citing works

Natural history and prognostic impact of oligoclonal humoral response in patients with multiple myeloma after autologous stem cell transplantation: long-term results from a single institution

Tovar, N., de Larrea, C. F., Aróstegui, J. I., Cibeira, M. T., Rosiñol, L., Rovira, M., Elena, M. S., Filella, X., Yagüe, J., & Bladé, J. (2013) · Haematologica · doi:10.3324/haematol.2013.084350 · Cited by 55 · see citing works

How I treat acute myeloid leukemia presenting with preexisting comorbidities

Ofran, Y., Tallman, M. S., & Rowe, J. M. (2016) · Blood · doi:10.1182/blood-2016-01-635060 · Cited by 52 · see citing works

Patterns of relapse and progression in multiple myeloma patients after auto-SCT: implications for patients’ monitoring after transplantation

Zamarin, D., Giralt, S. A., Landau, H. J., Lendvai, N. K., Lesokhin, A. M., Chung, D. J., Koehne, G., Chimento, D., Devlin, S. M., Riedel, E., et al. (2012) · Bone Marrow Transplantation · doi:10.1038/bmt.2012.151 · Cited by 46 · see citing works

Second autologous transplant as salvage therapy in multiple myeloma

Atanackovic, D., & Schilling, G. (2013) · British Journal of Haematology · doi:10.1111/bjh.12579 · Cited by 42 · see citing works

Progress in Myeloma — A Monoclonal Breakthrough

Rajkumar, S. V., & Kyle, R. A. (2016) · New England Journal of Medicine · doi:10.1056/nejme1609835 · Cited by 40 · see citing works

Venetoclax Monotherapy for Relapsed/Refractory Multiple Myeloma: Safety and Efficacy Results from a Phase I Study

Kumar, S. K., Vij, R., Kaufman, J. L., Mikhael, J. R., Facon, T. T. F., Pegourié, B., Benboubker, L., Gasparetto, C., Amiot, M., Moreau, P., et al. (2016) · Blood · doi:10.1182/blood.v128.22.488.488 · Cited by 40 · see citing works

Updated data from a phase II dose finding trial of single agent isatuximab (SAR650984, anti-CD38 mAb) in relapsed/refractory multiple myeloma (RRMM).

Richter, J. R., Martin, T. G., Vij, R., Cole, C. E., Atanackovic, D., Zonder, J. A., Kaufman, J. L., Mikhael, J. R., Bensinger, W., Dimopoulos, M. A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.8005 · Cited by 36 · see citing works

Oligoclonal bands and immunoglobulin isotype switch during monitoring of patients with multiple myeloma and autologous hematopoietic cell transplantation: a 16-year experience

Alejandre, M. E., Madalena, L. B., Pavlovsky, M. A., Facio, M. L., Corrado, C., Milone, G., Bresciani, P. D., Fraind, S., Pavlovsky, S., & Pizzolato, M. (2010) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2010.050 · Cited by 34 · see citing works

Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed Lenalidomide Refractory Multiple Myeloma (MM)

Lacy, M. Q., LaPlant, B. R., Laumann, K. M., Kumar, S. K., Gertz, M. A., Hayman, S. R., Buadi, F. K., Dispenzieri, A. A., Lust, J. A., Kapoor, P., et al. (2014) · Blood · doi:10.1182/blood.v124.21.304.304 · Cited by 30 · see citing works

Selinexor and Low Dose Dexamethasone (Sd) in Patients with Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib and Anti-CD38 Ab Refractory Multiple Myeloma (MM): STORM Study

Vogl, D. T., Dingli, D., Cornell, R. F., Huff, C. A., Jagannath, S., Bhutani, D., Baz, R., Nooka, A. K., Richter, J. R., Cole, C. E., et al. (2016) · Blood · doi:10.1182/blood.v128.22.491.491 · Cited by 28 · see citing works

A Waldenström amyloidoma

Rashidi, A., & Fisher, S. I. (2016) · Blood · doi:10.1182/blood-2016-06-720862 · Cited by 28 · see citing works

Drugs that lack single-agent activity: are they worth pursuing in combination?

Gyawali, B., & Prasad, V. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.27 · Cited by 28 · see citing works

Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant

Gaballa, S. R., Saliba, R. M., Srour, S. A., Lu, G. G., Brammer, J. E., Shah, N. D., Bashir, Q., Patel, K. K., Bock, F. M., Parmar, S., et al. (2016) · American Journal of Hematology · doi:10.1002/ajh.24487 · Cited by 27 · see citing works

Clinical Efficacy of Daratumumab, Pomalidomide and Dexamethasone in Relapsed, Refractory Myeloma Patients: Utility of Retreatment with Daratumumab Among Refractory Patients

Nooka, A. K., Joseph, N. S., Boise, L. H., Gleason, C. L., Kaufman, J. L., & Lonial, S. (2016) · Blood · doi:10.1182/blood.v128.22.492.492 · Cited by 27 · see citing works

A phase I/IIa Study of the CD38 Antibody MOR202 in Combination With Pomalidomide or Lenalidomide in Patients With Relapsed or Refractory Multiple Myeloma

Chatterjee, M., Raab, M. S., Goldschmidt, H., Agis, H., Blau, I. W., Einsele, H., Engelhardt, M. M., Ferstl, B., Günther, A., Röllig, C., et al. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.03.112 · Cited by 26 · see citing works

Venetoclax Combined with Bortezomib and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma

Moreau, P., Chanan-Khan, A. A., Roberts, A. W., Agarwal, A. B., Facon, T. T. F., Kumar, S. K., Touzeau, C., Cordero, J., Ross, J. A., Munasinghe, W. P., et al. (2016) · Blood · doi:10.1182/blood.v128.22.975.975 · Cited by 24 · see citing works

A staged approach with vincristine, adriamycin, and dexamethasone followed by bortezomib, thalidomide, and dexamethasone before autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma

Chim, C. S., Lie, A. K. W., Chan, E. Y. T., Leung, Y.-H., Cheung, S., Chan, S. Y. T., Liang, R. H. S., & Kwong, Y. (2010) · Annals of Hematology · doi:10.1007/s00277-010-0959-4 · Cited by 16 · see citing works

MM-007: A phase 3 trial comparing the efficacy and safety of pomalidomide (POM), bortezomib (BORT), and low-dose dexamethasone (LoDEX [PVD]) versus BORT and LoDEX (VD) in subjects with relapsed or refractory multiple myeloma (RRMM).

Richardson, P. G. G., Bensmaine, A., Doerr, T., Wang, J., Zaki, M. H., & MM-007 Study Investigators (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.tps8610 · Cited by 10 · see citing works

Daratumumab Single Agent and Daratumumab Plus Pomalidomide and Dexametasone in Relapsed/Refractory Multiple Myeloma: A Real Life Retrospective Evaluation

Branca, A., Buros, A. F., Yoon, D., Suva, L. J., Weinhold, N., Rasche, L., Schinke, C., Thanendrarajan, S., Mohan, M., Harcourt, C., et al. (2016) · Blood · doi:10.1182/blood.v128.22.4516.4516 · Cited by 9 · see citing works

Efficacy and safety of ixazomib plus lenalidomide-dexamethasone (IRd) vs placebo-rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM) by cytogenetic risk status in the global phase III Tourmaline-MM1 study.

Richardson, P. G. G., Avet‐Loiseau, H., Palumbo, A. P., Viterbo, L., Nagler, A., Ganly, P. S., Yehuda, D. B., Miguel, J. F. S., Rajkumar, S. V., Pour, L., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.8018 · Cited by 9 · see citing works

Oligoclonal reconstitution masquerading as myeloma relapse

Chim, C. S., & Chan, E. Y. T. (2012) · Annals of Hematology · doi:10.1007/s00277-012-1624-x · Cited by 3 · see citing works

A Phase I/IIa Study of the CD38 Antibody MOR202 Alone and in Combination with Pomalidomide or Lenalidomide in Patients with Relapsed or Refractory Multiple Myeloma

Raab, M. S., Chatterjee, M., Goldschmidt, H., Agis, H., Blau, I., Einsele, H., Engelhardt, M., Ferstl, B., Gramatzki, M., Röllig, C., et al. (2016) · Blood · doi:10.1182/blood.v128.22.1152.1152

Final Results of Phase 1 MMRC Trial of Selinexor, Carfilzomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM)

Jakubowiak, A., Jasielec, J., Rosenbaum, C. A., Cole, C. E., Chari, A., Nam, J., Severson, E., Stephens, L. A., McDonnell, K., Rosebeck, S., et al. (2016) · Blood · doi:10.1182/blood.v128.22.973.973

Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma.

Raje, N., Berdeja, J., Lin, Y., Siegel, D., Jagannath, S., Madduri, D., Liedtke, M., Rosenblatt, J., Maus, M. V., Turka, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817226 · Cited by 1,730 · see citing works

B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches

Shah, N., Chari, A., Scott, E., Mezzi, K., & Usmani, S. Z. (2020) · Leukemia · doi:10.1038/s41375-020-0734-z · Cited by 490 · see citing works

Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial

Kumar, S. K., Harrison, S. J., Cavo, M., de la Rubia, J., Popat, R., Gasparetto, C., Hungria, V., Salwender, H. J., Suzuki, K., Kim, I., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30525-8 · Cited by 404 · see citing works

Epidemiology, Staging, and Management of Multiple Myeloma

Padala, S. A., Barsouk, A., Barsouk, A., Rawla, P., Vakiti, A., Kolhe, R., Kota, V., & Ajebo, G. H. (2021) · Medical Sciences · doi:10.3390/medsci9010003 · Cited by 332 · see citing works

γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma

Pont, M. J., Hill, T., Cole, G. O., Abbott, J. J., Kelliher, J. L., Salter, A. I., Hudecek, M., Comstock, M., Rajan, A., Patel, B. K. R., et al. (2019) · Blood · doi:10.1182/blood.2019000050 · Cited by 332 · see citing works

Multiple Myeloma: Available Therapies and Causes of Drug Resistance

Pinto, V., Bergantim, R., Caires, H. R., Seca, H., Guimarães, J. E., & Vasconcelos, M. H. (2020) · Cancers · doi:10.3390/cancers12020407 · Cited by 233 · see citing works

A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma

Wang, D., Wang, J., Hu, G., Wang, W., Xiao, Y., Cai, H., Jiang, L., Li, M., Yang, Y., Zhou, X., et al. (2021) · Blood · doi:10.1182/blood.2020008936 · Cited by 206 · see citing works

Repurposing of auranofin: Thioredoxin reductase remains a primary target of the drug

Zhang, X., Selvaraju, K., Saei, A. A., D’Arcy, P., Zubarev, R. A., Arnér, E. S. J., & Linder, S. T. (2019) · Biochimie · doi:10.1016/j.biochi.2019.03.015 · Cited by 173 · see citing works

Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma

Richardson, P. G. G., Oriol, A., Larocca, A., Bladé, J., Cavo, M., Rodríguez‐Otero, P., Leleu, X. P., Nadeem, O., Hiemenz, J. W., Hassoun, H., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.02259 · Cited by 157 · see citing works

Targeting cancer-associated fibroblasts in the bone marrow prevents resistance to CART-cell therapy in multiple myeloma

Sakemura, R. L., Hefazi, M., Siegler, E. L., Cox, M. J., Larson, D. P., Hansen, M. J., Roman, C. M., Schick, K. J., Can, İ., Tapper, E. E., et al. (2022) · Blood · doi:10.1182/blood.2021012811 · Cited by 148 · see citing works

Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma

Campbell, K. S., Cohen, A. D., & Pazina, T. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02551 · Cited by 125 · see citing works

Treatment options for triple-class refractory multiple myeloma.

Mikhael, J. (2020) · Clinical Lymphoma Myeloma and Leukemia · doi:10.1016/j.clml.2019.09.621 · Cited by 126 · see citing works

Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains

Lam, N., Trinklein, N. D., Buelow, B., Patterson, G. H., Ojha, N., & Kochenderfer, J. N. (2020) · Nature Communications · doi:10.1038/s41467-019-14119-9 · Cited by 122 · see citing works

European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias

Gavriatopoulou, M., Musto, P., Caers, J., Merlini, G., Kastritis, E., van de Donk, N. W. C. J., Gay, F., Hegenbart, U., Hájek, R., Zweegman, S., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0209-7 · Cited by 103 · see citing works

Tumor-associated macrophages in multiple myeloma: advances in biology and therapy

Sun, J., Park, C., Guenthner, N., Gurley, S., Zhang, L.-N., Lubben, B., Adebayo, O., Bash, H., Chen, Y., Maksimos, M., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003975 · Cited by 85 · see citing works

Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma

Lin, L., Cho, S., Xing, L., Wen, K., Li, Y., Yu, T., Hsieh, P. A., Chen, H., Kurtoğlu, M., Zhang, Y., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0951-5 · Cited by 90 · see citing works

Emerging agents and regimens for multiple myeloma

Yang, Y., Li, Y., Gu, H., Dong, M., & Cai, Z. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00980-5 · Cited by 87 · see citing works

Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma

Costa, L. J., Davies, F. E., Monohan, G. P., Kovacsovics, T. J., Burwick, N. R., Jakubowiak, A. J., Kaufman, J. L., Hong, W., Dail, M., Salem, A. H., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020004146 · Cited by 87 · see citing works

FTO promotes multiple myeloma progression by posttranscriptional activation of HSF1 in an m6A-YTHDF2-dependent manner

Xu, A., Zhang, J., Zuo, L., Yan, H., Chen, L., Zhao, F., Fan, F., Xu, J., Zhang, B., Zhang, Y., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.12.012 · Cited by 85 · see citing works

The NF-κB Activating Pathways in Multiple Myeloma

Roy, P., Sarkar, U. A., & Basak, S. (2018) · Biomedicines · doi:10.3390/biomedicines6020059 · Cited by 85 · see citing works

MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1–2a trial

Raab, M. S., Engelhardt, M. M., Blank, A., Goldschmidt, H., Agis, H., Blau, I. W., Einsele, H., Ferstl, B., Schub, N., Röllig, C., et al. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(19)30249-2 · Cited by 82 · see citing works

Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study

Schjesvold, F. H., Dimopoulos, M. A., Delimpasi, S., Robak, P., Coriu, D., Legiec, W., Pour, L., Špička, I., Masszi, T., Doronin, V., et al. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(21)00381-1 · Cited by 82 · see citing works

Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma

Bae, J. E., Accardi, F., Hideshima, T., Tai, Y., PRABHALA, R. H., Shambley, A., Wen, K., Rowell, S. M., Richardson, P. G. G., Munshi, N. C., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01301-6 · Cited by 81 · see citing works

Role of the RANK/RANKL Pathway in Multiple Myeloma

Raje, N. S., Bhatta, S. S., & Terpos, E. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1537 · Cited by 80 · see citing works

Mass Spectrometry for Identification, Monitoring, and Minimal Residual Disease Detection of M-Proteins

Zajec, M., Langerhorst, P., VanDuijn, M. M., Gloerich, J., Russcher, H., van Gool, A. J., Luider, T. M., Joosten, I., de Rijke, Y. B., & Jacobs, J. F. M. (2020) · Clinical Chemistry · doi:10.1093/clinchem/hvz041 · Cited by 75 · see citing works

ALDH and cancer stem cells: Pathways, challenges, and future directions in targeted therapy

Lavudi, K., Nuguri, S. M., Pandey, P., Kokkanti, R. R., & Wang, Q.-E. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.123033 · Cited by 76 · see citing works

A phase I study of anti‐BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia

Li, C., Cao, W., Que, Y., Wang, Q., Xiao, Y., Gu, C., Wang, D., Wang, J., Jiang, L., Xu, H., et al. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.346 · Cited by 72 · see citing works

Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma

Jakubowiak, A. J., Jasielec, J. K., Rosenbaum, C. A., Cole, C. E., Chari, A., Mikhael, J. R., Nam, J., McIver, A., Severson, E., Stephens, L. A., et al. (2019) · British Journal of Haematology · doi:10.1111/bjh.15969 · Cited by 69 · see citing works

A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD–56-positive Multiple Myeloma

Ailawadhi, S., Kelly, K. R., Vescio, R. A., Jagannath, S., Wolf, J. L., Gharibo, M. M., Sher, T., Bojanini, L., Kirby, M. W., & Chanan-Khan, A. A. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.08.018 · Cited by 65 · see citing works

IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies

Bergaggio, E., Riganti, C., Garaffo, G., Vitale, N., Mereu, E., Bandini, C., Pellegrino, E., Pullano, V., Omedè, P., Todoerti, K., et al. (2018) · Blood · doi:10.1182/blood-2018-05-850826 · Cited by 62 · see citing works

BCMA in Multiple Myeloma—A Promising Key to Therapy

Kleber, M., Ntanasis‐Stathopoulos, I., & Terpos, E. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10184088 · Cited by 61 · see citing works

Delivery of Therapeutic RNA to the Bone Marrow in Multiple Myeloma Using CD38‐Targeted Lipid Nanoparticles

Tarab‐Ravski, D., Hazan‐Halevy, I., Goldsmith, M., Stotsky‐Oterin, L., Breier, D., Naidu, G. S., Aitha, A., Diesendruck, Y., Ng, B. D., Barsheshet, H., et al. (2023) · Advanced Science · doi:10.1002/advs.202301377 · Cited by 60 · see citing works

hsa_circ_0007841: A Novel Potential Biomarker and Drug Resistance for Multiple Myeloma

Gao, M., Li, C., Xiao, H., Dong, H., Jiang, S., Fu, Y., & Gong, L. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01261 · Cited by 59 · see citing works

Circ-SMARCA5 suppresses progression of multiple myeloma by targeting miR-767-5p

Liu, H., Wu, Y., Wang, S., Jiang, J., Zhang, C., Jiang, Y., Wang, X., Hong, L., & Huang, H. (2019) · BMC Cancer · doi:10.1186/s12885-019-6088-0 · Cited by 58 · see citing works

Molecular basis of clonal evolution in multiple myeloma

Furukawa, Y., & Kikuchi, J. (2020) · International Journal of Hematology · doi:10.1007/s12185-020-02829-6 · Cited by 56 · see citing works

Novel Therapies for Metastatic Triple-Negative Breast Cancer: Spotlight on Immunotherapy and Antibody-Drug Conjugates

Nagayama, A., Vidula, N., & Bardia, A. (2021) · ONCOLOGY · doi:10.46883/onc.2021.3505.0249 · Cited by 56 · see citing works

Molecular Players in Hematologic Tumor Cell Trafficking

Redondo-Muñóz, J., Garcı́a-Pardo, A., & Teixidó, J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00156 · Cited by 55 · see citing works

Selective elimination of immunosuppressive T cells in patients with multiple myeloma

Awwad, M. H. S., Mahmoud, A., Bruns, H., Echchannaoui, H., Kriegsmann, K., Lutz, R., Raab, M. S., Bertsch, U., Munder, M., Jauch, A. S., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01172-x · Cited by 54 · see citing works

Daratumumab- 225 Actinium conjugate demonstrates greatly enhanced antitumor activity against experimental multiple myeloma tumors

Dawicki, W., Allen, K. J. H., Jiao, R., Malo, M. E., Helal, M. H. S., Berger, M. S., Ludwig, D. L., & Dadachova, E. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1607673 · Cited by 55 · see citing works

BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma

Cho, S., Lin, L., Xing, L., Li, Y., Yu, T., Anderson, K. C., & Tai, Y. (2020) · Cancers · doi:10.3390/cancers12061473 · Cited by 54 · see citing works

Improving outcomes for patients with relapsed multiple myeloma: Challenges and considerations of current and emerging treatment options

Ramasamy, K., Gay, F., Weisel, K. C., Zweegman, S., Mateos, M., & Richardson, P. G. G. (2021) · Blood Reviews · doi:10.1016/j.blre.2021.100808 · Cited by 54 · see citing works

Isatuximab: A Review of Its Use in Multiple Myeloma

Frampton, J. E. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00827-0 · Cited by 51 · see citing works

Immunomodulatory Effects of Drugs for Effective Cancer Immunotherapy

Matsushita, M., & Kawaguchi, M. (2018) · Journal of Oncology · doi:10.1155/2018/8653489 · Cited by 45 · see citing works

Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma

Panowski, S. H., Kuo, T. C., Zhang, Y., Chen, A., Geng, T., Aschenbrenner, L., Kamperschroer, C., Pascua, E., Chen, W., Delaria, K., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0007 · Cited by 48 · see citing works

hsa_circRNA_101237: A Novel Diagnostic and Prognostic Biomarker and Potential Therapeutic Target for Multiple Myeloma

Liu, X., Tang, H. T., Liu, J., & Wang, X. (2020) · Cancer Management and Research · doi:10.2147/cmar.s241089 · Cited by 44 · see citing works

A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma

Laubach, J. P., Liu, C., Raje, N. S., Yee, A. J., Armand, P. A., Schlossman, R. L., Rosenblatt, J. M., Hedlund, J. A., Martin, M. G., Reynolds, C. H., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1325 · Cited by 43 · see citing works

VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo

Yu, T., Chaganty, B., Lin, L., Xing, L., Ramakrishnan, B., Wen, K., Hsieh, P. A., Wollacott, A., Viswanathan, K., Adari, H., et al. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-00378-z · Cited by 43 · see citing works

Safety and Efficacy of CAR-T Cell Targeting BCMA in Patients with Multiple Myeloma Co-Infected with Chronic Hepatitis B Virus

Han, L., Zhou, J., Zhou, K., Zhu, X., Zhao, L., Fang, B., Yin, Q., Wei, X., Zhou, H., Li, L., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000927 · Cited by 42 · see citing works

Adaptive Natural Killer Cells Facilitate Effector Functions of Daratumumab in Multiple Myeloma

Cho, H., Kim, K. H., Lee, H., Kim, C. G., Chung, H., Choi, Y. S., Park, S., Cheong, J., Min, Y. H., Shin, E., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3418 · Cited by 42 · see citing works

The Safety of Bridging Radiation with Anti-BCMA CAR T-Cell Therapy for Multiple Myeloma

Manjunath, S. H., Cohen, A. D., Lacey, S. F., Suhoski, M. M., Garfall, A. L., Melenhorst, J. J., Maxwell, R., Arscott, W. T., Maity, A. M., Jones, J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0308 · Cited by 42 · see citing works

Pathogenesis and treatment of multiple myeloma

Yang, P., Qu, Y., Wang, M., Chu, B., Chen, W., Zheng, Y., Niu, T., & Qian, Z. (2022) · MedComm · doi:10.1002/mco2.146 · Cited by 42 · see citing works

Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma

Terpos, E., Ramasamy, K., Maouche, N., Minařík, J., Ntanasis‐Stathopoulos, I., Katodritou, E., Jenner, M. W., Plonková, H., Gavriatopoulou, M., Vallance, G. D., et al. (2020) · Annals of Hematology · doi:10.1007/s00277-020-03981-z · Cited by 41 · see citing works

Advancements in Cancer Immunotherapies

Roy, R., Singh, S. K., & Misra, S. (2022) · Vaccines · doi:10.3390/vaccines11010059 · Cited by 41 · see citing works

Discovery and Early Clinical Development of Selective Immunoproteasome Inhibitors

Kirk, C. J., Muchamuel, T., Wang, J., & Fan, R. (2021) · Cells · doi:10.3390/cells11010009 · Cited by 40 · see citing works

Novel BCMA-OR-CD38 tandem-dual chimeric antigen receptor T cells robustly control multiple myeloma

Feng, Y., Liu, X., Li, X., Zhou, Y., Song, Z., Zhang, J., Shi, B., & Wang, J. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1959102 · Cited by 35 · see citing works

Comparison of CAR T-cell and bispecific antibody as third-line or later-line treatments for multiple myeloma: a meta-analysis

Liang, X.-J., Wang, Y.-F., Luo, B.-W., Lin, B., Lu, W.-X., Tian, S., Liu, D., & Wang, L. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010064 · Cited by 37 · see citing works

ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma

Dhakal, B., Shah, N. D., Kansagra, A. J., Kumar, A., Lonial, S., Garfall, A. L., Cowan, A. J., Poudyal, B. S., Costello, C. L., Gay, F., et al. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.03.019 · Cited by 38 · see citing works

Decitabine shows potent anti-myeloma activity by depleting monocytic myeloid-derived suppressor cells in the myeloma microenvironment

Zhou, J., Shen, Q., Lin, H., Hu, L., Li, G., & Zhang, X. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2790-6 · Cited by 35 · see citing works

Efficacy and toxicity of histone deacetylase inhibitors in relapsed/refractory multiple myeloma: Systematic review and meta‑analysis of clinical trials

Gao, X., Shen, L., Li, X., & Liu, J. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7704 · Cited by 34 · see citing works

Patient-Reported Factors in Treatment Satisfaction in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Chari, A., Romanus, D., DasMahapatra, P., Hoole, M., Lowe, M., Curran, C., Campbell, S., & Bell, J. A. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0724 · Cited by 34 · see citing works

CRS-related coagulopathy in BCMA targeted CAR-T therapy: a retrospective analysis in a phase I/II clinical trial

Shao, M., Yu, Q., Teng, X., Guo, X., Wei, G., Xu, H., Cui, J., Chang, A. H., Hu, Y., & Huang, H. (2021) · Bone Marrow Transplantation · doi:10.1038/s41409-021-01226-9 · Cited by 35 · see citing works

Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US

Davies, F. E., Rifkin, R. M., Costello, C. L., Morgan, G. J., Usmani, S. Z., Abonour, R., Palumbo, A. P., Romanus, D., Hájek, R., Terpos, E., et al. (2021) · Annals of Hematology · doi:10.1007/s00277-021-04534-8 · Cited by 34 · see citing works

Indirubin-3’-monoxime acts as proteasome inhibitor: Therapeutic application in multiple myeloma

Yu, Z., Wei, X., Liu, L., Sun, H., Fang, T., Wang, L., Li, Y., Sui, W., Wang, K., He, Y., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103950 · Cited by 33 · see citing works

Bortezomib-Loaded Mesoporous Silica Nanoparticles Selectively Alter Metabolism and Induce Death in Multiple Myeloma Cells

Nigro, A., Frattaruolo, L., Fava, M., Napoli, I. D., Greco, M., Comandé, A., Santo, M. D., PELLEGRINO, M. A., Ricci, E. D., Giordano, F., et al. (2020) · Cancers · doi:10.3390/cancers12092709 · Cited by 33 · see citing works

AXL Receptor Tyrosine Kinase as a Therapeutic Target in Hematological Malignancies: Focus on Multiple Myeloma

Yan, S., Vandewalle, N., Beule, N. D., Faict, S., Maes, K., Bruyne, E. D., Menu, E., Vanderkerken, K., & Veirman, K. D. (2019) · Cancers · doi:10.3390/cancers11111727 · Cited by 32 · see citing works

Cost-Effectiveness of Alemtuzumab in the Treatment of Relapsing Forms of Multiple Sclerosis in the United States

Chirikov, V., Ma, I., Joshi, N., Patel, D. A., Smith, A. F., Giambrone, C., Cornelio, N., & Hashemi, L. (2018) · Value in Health · doi:10.1016/j.jval.2018.08.011 · Cited by 32 · see citing works

Impact of Minimal Residual Disease Detection by Next-Generation Flow Cytometry in Multiple Myeloma Patients with Sustained Complete Remission after Frontline Therapy

Terpos, E., Kostopoulos, I. V., Kastritis, E., Ntanasis‐Stathopoulos, I., Migkou, M., Rousakis, P., Argyriou, A., Kanellias, N., Fotiou, D., Eleutherakis‐Papaiakovou, E., et al. (2019) · HemaSphere · doi:10.1097/hs9.0000000000000300 · Cited by 31 · see citing works

Biological Background of Resistance to Current Standards of Care in Multiple Myeloma

Mogollón, P., Díaz-Tejedor, A., Algarín, E. M., Paíno, T., Garayoa, M., & Ocio, E. M. (2019) · Cells · doi:10.3390/cells8111432 · Cited by 30 · see citing works

ROS Overproduction Sensitises Myeloma Cells to Bortezomib-Induced Apoptosis and Alleviates Tumour Microenvironment-Mediated Cell Resistance

Caillot, M., Zylbersztejn, F., Maître, E., Bourgeais, J., Hérault, O., & Sola, B. (2020) · Cells · doi:10.3390/cells9112357 · Cited by 29 · see citing works

The Mitochondrial Protease LonP1 Promotes Proteasome Inhibitor Resistance in Multiple Myeloma

Maneix, L., Sweeney, M. A., Lee, S., Iakova, P. A., Moree, S. E., Sahin, E., Lulla, P., Yellapragada, S. V., Tsai, F., & Catic, A. (2021) · Cancers · doi:10.3390/cancers13040843 · Cited by 29 · see citing works

The LncRNA RP11-301G19.1/miR-582-5p/HMGB2 axis modulates the proliferation and apoptosis of multiple myeloma cancer cells via the PI3K/AKT signalling pathway

Wang, F., Luo, Y., Zhang, L., Younis, M., & Yuan, L. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-021-00309-5 · Cited by 33 · see citing works

Drug targets and resistance mechanisms in multiple myeloma

Naß, J., & Efferth, T. (2018) · Cancer Drug Resistance · doi:10.20517/cdr.2018.04 · Cited by 28 · see citing works

Ixazomib – the first oral proteasome inhibitor

Xie, J., Wan, N., Liang, Z., Zhang, T., & Jiang, J. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1523398 · Cited by 27 · see citing works

Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8+ cytotoxic T lymphocytes: immunotherapeutic application in vaccination and adoptive immunotherapy

Bae, J. E., Samur, M., Richardson, P. G. G., Munshi, N. C., & Anderson, K. C. (2019) · Leukemia · doi:10.1038/s41375-019-0414-z · Cited by 27 · see citing works

Real-world data on safety and efficacy of venetoclax-based regimens in relapsed/refractory t(11;14) multiple myeloma

Basali, D., Chakraborty, R., Rybicki, L., Rosko, N., Reed, J., Karam, M., Schlueter, K., Dysert, H., Kalaycio, M., & Valent, J. (2020) · British Journal of Haematology · doi:10.1111/bjh.16454 · Cited by 27 · see citing works

Novel targets for the treatment of relapsing multiple myeloma

Giuliani, N., Accardi, F., Marchica, V., Palma, B. D., Storti, P., Toscani, D., Vicario, E., & Malavasi, F. (2019) · Expert Review of Hematology · doi:10.1080/17474086.2019.1624158 · Cited by 27 · see citing works

Activity of TAS4464, a novel NEDD8 activating enzyme E1 inhibitor, against multiple myeloma via inactivation of nuclear factor κB pathways

Muraoka, H., Yoshimura, C., Kawabata, R., Tsuji, S., Hashimoto, A., Ochiiwa, H., Nakagawa, F., Fujioka, Y., Matsuo, K., & Ohkubo, S. (2019) · Cancer Science · doi:10.1111/cas.14209 · Cited by 27 · see citing works

Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies

Schriewer, L., Schütze, K., Petry, K., Hambach, J., Fumey, W., Koenigsdorf, J., Baum, N., Menzel, S., Rissiek, B., Riecken, K., et al. (2020) · Theranostics · doi:10.7150/thno.38533 · Cited by 26 · see citing works

Salvage second transplantation in relapsed multiple myeloma

Dhakal, B., D’Souza, A., Kleman, A., Chhabra, S., Mohan, M., & Hari, P. (2020) · Leukemia · doi:10.1038/s41375-020-1005-8 · Cited by 26 · see citing works

An Overview of CAR T Cell Mediated B Cell Maturation Antigen Therapy

Quazi, S. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.12.003 · Cited by 24 · see citing works

The deubiquitinase OTUD1 regulates immunoglobulin production and proteasome inhibitor sensitivity in multiple myeloma

Vdovin, A., Jelı́nek, T., Žihala, D., Ševčíková, T., Ďurech, M., Sahinbegovic, H., Šnaurová, R., Radhakrishnan, D., Turi, M., Chyra, Z., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34654-2 · Cited by 27 · see citing works

Ixazomib: a novel drug for multiple myeloma

Zanwar, S., Abeykoon, J. P., & Kapoor, P. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1518129 · Cited by 26 · see citing works

Survival trends and prognostic factors in patients with solitary plasmacytoma of bone: A population‐based study

Shen, X., Liu, S., Wu, C., Wang, J., Li, J., & Chen, L. (2020) · Cancer Medicine · doi:10.1002/cam4.3533 · Cited by 25 · see citing works

Signaling Lymphocytic Activation Molecule Family-7 Alleviates Corneal Inflammation by Promoting M2 Polarization

Zhu, S., Chen, Y., Lao, J., Wu, C., Zhan, X., Wu, Y., Shang, Y., Zou, Z., Zhou, J., Ji, X., et al. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa445 · Cited by 24 · see citing works

Focus on monoclonal antibodies targeting B‐cell maturation antigen (BCMA) in multiple myeloma: update 2021

Demel, I., Bago, J., Hájek, R., & Jelı́nek, T. (2020) · British Journal of Haematology · doi:10.1111/bjh.17235 · Cited by 25 · see citing works

Upregulated expression and function of the α 4 β 1 integrin in multiple myeloma cells resistant to bortezomib

Sevilla‐Movilla, S., Arellano‐Sánchez, N., Martínez‐Moreno, M., Gajate, C., Sánchez‐Vencells, A., Valcárcel, L. V., Agirre, X., Valeri, A., Martínez‐López, J., Prósper, F., et al. (2020) · The Journal of Pathology · doi:10.1002/path.5480 · Cited by 23 · see citing works

Hematopoeitic Cell Transplantation and CAR T-Cell Therapy: Complements or Competitors?

Goldsmith, S. R., Ghobadi, A., & DiPersio, J. F. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.608916 · Cited by 23 · see citing works

Rapid Progress in Immunotherapies for Multiple Myeloma: An Updated Comprehensive Review

Nishida, H. (2021) · Cancers · doi:10.3390/cancers13112712 · Cited by 23 · see citing works

lncRNA ST3GAL6‑AS1 promotes invasion by inhibiting hnRNPA2B1‑mediated ST3GAL6 expression in multiple myeloma

Shen, Y., Feng, Y., Li, F., Jia, Y., Peng, Y., Zhao, W., Hu, J., & He, A. (2021) · International Journal of Oncology · doi:10.3892/ijo.2021.5185 · Cited by 23 · see citing works

Melflufen for relapsed and refractory multiple myeloma

Oriol, A., Larocca, A., Leleu, X. P., Hájek, R., Hassoun, H., Rodríguez‐Otero, P., Paner, A., Schjesvold, F. H., Gullbo, J., & Richardson, P. G. G. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1808884 · Cited by 23 · see citing works

Efficacy and Safety of CAR-Modified T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma: A Meta-Analysis of Prospective Clinical Trials

Xiang, X., He, Q., Ou, Y., Wang, W., & Wu, Y. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.544754 · Cited by 22 · see citing works

Antibody-drug conjugates for multiple myeloma

McMillan, A., Warcel, D., & Popat, R. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1802422 · Cited by 22 · see citing works

Pan-PIM kinase inhibitors enhance Lenalidomide's anti-myeloma activity via cereblon-IKZF1/3 cascade

Zheng, J. J., Sha, Y., Roof, L., Foreman, O., Lazarchick, J. J., Venkata, J. K., Kozlowski, C., Gasparetto, C., Chao, N. J. A., Ebens, A. J., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.10.003 · Cited by 21 · see citing works

Directly targeting c-Myc contributes to the anti-multiple myeloma effect of anlotinib

Cao, Y., Shan, H., Liu, M., Liu, J., Zhang, Z., Xu, X., Liu, Y., Xu, H., Lei, H., Yu, M., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03685-w · Cited by 21 · see citing works

Frequent methylation of the tumour suppressor miR‐1258 targeting PDL1: implication in multiple myeloma‐specific cytotoxicity and prognostification

Wang, L. Q., Kumar, S. K., Calin, G. A., Li, Z., & Chim, C. S. (2020) · British Journal of Haematology · doi:10.1111/bjh.16517 · Cited by 20 · see citing works

Epigenetic silencing of long non-coding RNA BM742401 in multiple myeloma: impact on prognosis and myeloma dissemination

Li, Z., Kumar, S. K., Jin, D., Călin, G. A., Chng, W. J., Siu, K., Poon, M.-W., & Chim, C. S. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01504-4 · Cited by 20 · see citing works

Polyphyllin VII, a novel moesin inhibitor, suppresses cell growth and overcomes bortezomib resistance in multiple myeloma

Wang, H., Xiao, X., Li, Z., Luo, S., Hu, L., Yi, H. J., Xiang, R., Zhu, Y., Wang, Y., Zhu, L., et al. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215647 · Cited by 20 · see citing works

Pterostilbene inhibits nutrient metabolism and induces apoptosis through AMPK activation in multiple myeloma cells

Mei, H., Yu, X. M., Mei, H., Fang, B., Wang, Q., Cao, D., Hu, Y., & Guo, T. (2018) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2018.3857 · Cited by 20 · see citing works

Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma

Zanwar, S., Ho, M., Kapoor, P., Dispenzieri, A. A., Lacy, M. Q., Gertz, M. A., Buadi, F. K., Hayman, S. R., Dingli, D., Kourelis, T., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01433-9 · Cited by 20 · see citing works

Treatment Satisfaction and Burden of Illness in Patients with Newly Diagnosed Multiple Myeloma

Rifkin, R. M., Bell, J. A., DasMahapatra, P., Hoole, M., Lowe, M., Curran, C., Campbell, S., Hou, P., & Romanus, D. (2019) · PharmacoEconomics - Open · doi:10.1007/s41669-019-00184-9 · Cited by 19 · see citing works

New Possibilities of Treatment for Relapsed/Refractory Multiple Myeloma: A Literature Review

Votyakova, O. M. (2017) · Clinical oncohematology · doi:10.21320/2500-2139-2017-10-4-425-434 · Cited by 1 · see citing works

The Role of Novel Antibody Strategies in Relapsed/Refractory Multiple Myeloma

Nalley, C. (2018) · Oncology Times · doi:10.1097/01.cot.0000544332.45592.24

Current strategies for treatment of relapsed/refractory multiple myeloma

Laubach, J. P., Voorhees, P. M., Hassoun, H., Jakubowiak, A. J., Lonial, S., & Richardson, P. G. G. (2014) · Expert Review of Hematology · doi:10.1586/17474086.2014.882764 · Cited by 67 · see citing works

A Review on Therapeutic strategies of Relapsed and Refractory Multiple MyelomaPreprint

Mukherjee, D. (2021) · doi:10.31219/osf.io/bfj4z · Cited by 1 · see citing works

Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment

Morè, S., Petrucci, M. T., Corvatta, L., Fazio, F., Offidani, M., & Olivieri, A. (2020) · Pharmaceuticals · doi:10.3390/ph13120426 · Cited by 9 · see citing works